John T. Treace, Chief Executive Officer, 10% Owner at TREACE MEDICAL CONCEPTS, INC. (TMCI), bought 115,520 shares at $2.79 ($341K) on 2026-05-26, disclosed to the SEC on 2026-05-28.
CEO John T. Treace purchased 4,508 shares for $12,575.97 at $2.79, marking the largest insider purchase in the company's history. This significant buyback by the CEO suggests confidence in the stock's recovery potential following a steep 47.52% one-year decline.
The stock has surged 61.58% over the last 30 days, trading at $3.07, which is 160.17% above its 52-week low of $1.18 but still 60.54% below the 52-week high of $7.78.
Q2 2026 earnings on August 7, 2026, where the company reported a 4% revenue decline but raised full-year guidance on strong adoption of new bunion systems.
The company reported a Q2 2026 loss, and revenue dropped 4% year-over-year due to lower procedure-kit sales and a shift toward lower-priced minimally invasive products.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.79 | 4,508 | $13K | 3.7% |
| 2 | $2.87 | 49,810 | $143K | 42.0% |
| 3 | $3.02 | 61,202 | $185K | 54.3% |
| Total | $2.95 avg | 115,520 | $341K | 100% |
| Filing → |
| TMCI | BUY | 2026-06-11 | $211K | — | Filing → |
| TMCI | BUY | 2026-06-01 | $178K | — | Filing → |
| TMCI | BUY | 2026-05-14 | $376K | — | Filing → |